NEW YORK (GenomeWeb News)– Myriad Genetics disclosed last week that Crescendo Bioscience recorded $27.3 million in revenues and a net loss of $41.1 million in 2013. Myriad acquired the autoimmune diagnostics company for $245 million in March. Crescendo spent $12.1 million on R&D last year and $26.4 million on SG&A. It ended the year with $3.1 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: biobank of colorectal cancer organoids, ancient wolf genome analysis, and more.

With cloud computing becoming more attractive to researchers, Nature News offers some tips on how to get going.

In a series of articles, medical journals debate the necessity of conflict-of-interest policies.

Irwin Rose, who won the 2004 Nobel Prize in Chemistry for his work on ubiquitin-mediated protein degradation, has died.